Clinical outcomes after palbociclib with or without endocrine therapy in postmenopausal women with hormone receptor positive and HER2-negative metastatic breast cancer enrolled in the TREnd trial

Currently, there is limited data regarding the effectiveness of standard subsequent line therapies such as endocrine therapy, chemotherapy, or targeted agents after progression on CDK4/6 inhibitor-based regimens. This paper describes time-to-treatment failure beyond progression on palbociclib or pal...

Szczegółowa specyfikacja

Zapisane w:
Opis bibliograficzny
Wydane w:Breast Cancer Res
Główni autorzy: Rossi, Lorenzo, Biagioni, Chiara, McCartney, Amelia, Migliaccio, Ilenia, Curigliano, Giuseppe, Sanna, Giuseppina, Moretti, Erica, Minisini, Alessandro M., Cinieri, Saverio, Tondini, Carlo, Arpino, Grazia, Bernardo, Antonio, Martignetti, Angelo, Risi, Emanuela, Pestrin, Marta, Boni, Luca, Benelli, Matteo, Biganzoli, Laura, Di Leo, Angelo, Malorni, Luca
Format: Artigo
Język:Inglês
Wydane: BioMed Central 2019
Hasła przedmiotowe:
Short Report
Dostęp online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6542028/
https://ncbi.nlm.nih.gov/pubmed/31142370
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13058-019-1149-5
Etykiety: Dodaj etykietę
Nie ma etykietki, Dołącz pierwszą etykiete!

Podobne zapisy